AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8368548 — intervention group
Group type: COMPARATOR
Intervention: Duration of sensory block in SI group
Number of subjects: 40
Study 3519897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis (streptokinase)
Number of subjects: 302
Study 31473189 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTG-led trials initiated post-2003
Number of subjects: 34957
Study 31473189 — intervention group
Group type: COMPARATOR
Intervention: CCTG-led trials initiated pre-2003
Number of subjects: 34957
Study 31473189 — intervention group
Group type: COMPARATOR
Intervention: Studies with exclusion criteria based on renal dysfunction
Number of subjects: 34957
Study 31473189 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system studies
Number of subjects: 34957
Study 31856840 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy with a long interval (8-12 weeks)
Number of subjects: 160
Study 31856840 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy with a short interval (4-7 weeks)
Number of subjects: 160
Study 26961539 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 50 mg
Number of subjects: 40
Study 26961539 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 100 mg
Number of subjects: 40
Study 26961539 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg
Number of subjects: 40
Study 26961539 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg
Number of subjects: 40
Study 26961539 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of LCZ696
Number of subjects: 40
Study 25314578 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation (WBC) daily during intensified training (ITWBC)
Number of subjects: 10
Study 25314578 — intervention group
Group type: COMPARATOR
Intervention: Control group (ITCON) without WBC
Number of subjects: 10
Study 23249889 — intervention group
Group type: EXPERIMENTAL
Intervention: Distally locked long cephalomedullary nails
Number of subjects: 11
Study 23249889 — intervention group
Group type: COMPARATOR
Intervention: Unlocked long cephalomedullary nails
Number of subjects: 11
Study 21667042 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9450 (10 mg)
Number of subjects: 10
Study 21667042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21667042 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 19618579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined stage (posterior incline)
Number of subjects: 8
Study 19618579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined stage (anterior incline)
Number of subjects: 8
Study 19618579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined stage (posterior)
Number of subjects: 8
Study 19618579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined stage (anterior)
Number of subjects: 8
Study 19618579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined stage (lateral)
Number of subjects: 8
Study 19618579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined stage (medial)
Number of subjects: 8
Study 17004188 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAP)
Number of subjects: 147
Study 17004188 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (CON)
Number of subjects: 147
Study 14529335 — intervention group
Group type: EXPERIMENTAL
Intervention: Preformed metal crown (SSC)
Number of subjects: 17
Study 14529335 — intervention group
Group type: COMPARATOR
Intervention: Cast adhesive coping (CAC)
Number of subjects: 17
Study 14529335 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SSC and CAC
Number of subjects: 17
Study 10843174 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued GH therapy (0.018 +/- 0.001 mg/kg day)
Number of subjects: 18
Study 10843174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10843174 — intervention group
Group type: EXPERIMENTAL
Intervention: Open phase GH therapy (0.016 mg/kg x day)
Number of subjects: 18
Study 10843174 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued GH treatment
Number of subjects: 18
Study 8809516 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 8809516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2052198 — intervention group
Group type: EXPERIMENTAL
Intervention: IV atropine (1.3 to 29.9 micrograms/kg)
Number of subjects: 8
Study 2052198 — intervention group
Group type: EXPERIMENTAL
Intervention: IV atropine (2.6 micrograms/kg)
Number of subjects: 8
Study 2052198 — intervention group
Group type: EXPERIMENTAL
Intervention: IV atropine (29.9 micrograms/kg)
Number of subjects: 8
Study 2052198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6686808 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid antacids (various doses)
Number of subjects: 0
Study 6686808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with anticholinergic and antacids
Number of subjects: 0
Study 6686808 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids (high dose)
Number of subjects: 0
Study 30649049 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned pregnancy
Number of subjects: 459
Study 30649049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambivalent pregnancy
Number of subjects: 459
Study 30649049 — intervention group
Group type: COMPARATOR
Intervention: Planned pregnancy
Number of subjects: 459
Study 28521867 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of moderate aerobic exercise
Number of subjects: 12
Study 28521867 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 12
Study 25477278 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D documentation system using Tumor Therapy Manager (TTM)
Number of subjects: 42
Study 25477278 — intervention group
Group type: COMPARATOR
Intervention: Conventional panendoscopy without TTM
Number of subjects: 42
Study 24406481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine treatment (6-week period)
Number of subjects: 9804
Study 24406481 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term sibutramine treatment
Number of subjects: 9804
Study 24406481 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and blood pressure reduction
Number of subjects: 9804
Study 24406481 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain and blood pressure increase
Number of subjects: 9804
Study 21971125 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Lateral Interbody Fusion (DLIF)
Number of subjects: 8
Study 21971125 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Lumbar Interbody Fusion (ALIF) with bilateral pedicle screw fixation (PSF)
Number of subjects: 8
Study 21971125 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Lateral Interbody Fusion (DLIF) with bilateral PSF
Number of subjects: 8
Study 21971125 — intervention group
Group type: COMPARATOR
Intervention: ALIF and DLIF groups supplemented with bilateral PSF
Number of subjects: 8
Study 19582880 — intervention group
Group type: EXPERIMENTAL
Intervention: CD163-positive tumors (n=10 out of 101 patients)
Number of subjects: 163
Study 19582880 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (5 x 5 Gy delivered in 1 week)
Number of subjects: 163
Study 19582880 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated group (n=78)
Number of subjects: 163
Study 19582880 — intervention group
Group type: EXPERIMENTAL
Intervention: CD163-positive tumors
Number of subjects: 163
Study 17131132 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelclair
Number of subjects: 20
Study 17131132 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Sucralfate and Mucaine)
Number of subjects: 20
Study 15267128 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinomial model
Number of subjects: 0
Study 12685918 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0
Study 9822094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I exercise protocol
Number of subjects: 34
Study 9822094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II exercise protocol (more intense)
Number of subjects: 34
Study 9822094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D exercise protocol (diabetic subjects)
Number of subjects: 34
Study 8739659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (specifics not detailed, but includes alprazolam for a subgroup of 26 patients)
Number of subjects: 47
Study 8739659 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (subgroup of 26 patients)
Number of subjects: 47
Study 8739659 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (NC)
Number of subjects: 47
Study 8739659 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder subgroup with agoraphobia (n = 24)
Number of subjects: 47
Study 2183864 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural pethidine 50 mg
Number of subjects: 30
Study 2183864 — intervention group
Group type: COMPARATOR
Intervention: i.m. pethidine 100 mg
Number of subjects: 30
Study 7416061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day modified fast with fluid intake of 2.7 to 3 liters/day containing around 200 kcal from juices and teas
Number of subjects: 12
Study 7416061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day modified fast
Number of subjects: 12
Study 31606835 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-irradiated sporulated oocysts
Number of subjects: 144
Study 31606835 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-irradiated sporulated oocysts
Number of subjects: 144
Study 31606835 — intervention group
Group type: COMPARATOR
Intervention: Non-immunized/challenged control (NIC)
Number of subjects: 144
Study 31606835 — intervention group
Group type: COMPARATOR
Intervention: Non-immunized/non-challenged control (NC)
Number of subjects: 144
Study 28597198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 162
Study 26295650 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFIRE S4
Number of subjects: 51
Study 26295650 — intervention group
Group type: COMPARATOR
Intervention: FBP
Number of subjects: 51
Study 26295650 — intervention group
Group type: COMPARATOR
Intervention: Low-dose (260 mAs)
Number of subjects: 51
Study 24586897 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Plus Automated Emails Group (TEG)
Number of subjects: 257
Study 24586897 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Treatment Group (TG)
Number of subjects: 257
Study 24586897 — intervention group
Group type: COMPARATOR
Intervention: Delayed-Treatment Waitlist Control Group (Control)
Number of subjects: 257
Study 22929542 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver with stepwise increases of PEEP achieving 45 cmH2O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to static compliance.
Number of subjects: 0
Study 22929542 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (ARDSNet strategy)
Number of subjects: 0
Study 22929542 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver with stepwise increases of PEEP
Number of subjects: 0
Study 20231532 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (5 mg folic acid, 50 microg vitamin B(12), 20 mg vitamin B(6))
Number of subjects: 650
Study 20231532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.2 mg folic acid, 4 microg vitamin B(12), 1.0 mg vitamin B(6))
Number of subjects: 650
Study 17430744 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural laxative mixture (Beverley-Travis), 2 tablespoons twice a day for 4 weeks
Number of subjects: 45
Study 17430744 — intervention group
Group type: COMPARATOR
Intervention: Prescribed laxatives (control group)
Number of subjects: 45
Study 17430744 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural laxative mixture
Number of subjects: 45
Study 16302356 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physiotherapist cycling training (3-4 times a week for 45 minutes over 8 weeks)
Number of subjects: 54
Study 16302356 — intervention group
Group type: COMPARATOR
Intervention: Not supervised training (cycling, stepping on stairs, or dynamic walking at home with the same duration and frequency)
Number of subjects: 54
Study 11932294 — intervention group
Group type: EXPERIMENTAL
Intervention: T enanthate (TE) 250 mg/wk im plus ethinylestradiol (EE2) 0.1 mg/d orally for 5.8 weeks
Number of subjects: 41
Study 11932294 — intervention group
Group type: COMPARATOR
Intervention: T enanthate (TE) alone
Number of subjects: 41
Study 11006054 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 additional risk factor
Number of subjects: 2149
Study 11006054 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 additional risk factors
Number of subjects: 2149
Study 11006054 — intervention group
Group type: COMPARATOR
Intervention: smoker only
Number of subjects: 2149
Study 11006054 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline risk factor status
Number of subjects: 2149
Study 7612363 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ranitidine 50 mg initially, followed by 50 mg every 6 hours
Number of subjects: 519
Study 7612363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 80 mg bolus initially, followed by 40 mg every 8 hours for 48 hours, then 40 mg every 12 hours until discharge
Number of subjects: 519
Study 2371367 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg)
Number of subjects: 15
Study 2371367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium amytal (250 mg)
Number of subjects: 15
Study 2371367 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (10 mg)
Number of subjects: 15
Study 889069 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 30
Study 889069 — intervention group
Group type: COMPARATOR
Intervention: Nalorphine
Number of subjects: 30
Study 889069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 889069 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (high doses)
Number of subjects: 30
Study 30964335 — intervention group
Group type: EXPERIMENTAL
Intervention: Diab and Nano videogames (9 sessions, ∼60 minutes each)
Number of subjects: 200
Study 30964335 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 200
Study 29077022 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g per day for six days)
Number of subjects: 17
Study 29077022 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 17
Study 29077022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carboxymethyl cellulose)
Number of subjects: 17
Study 29077022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26005337 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=31)
Number of subjects: 64
Study 26005337 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=33)
Number of subjects: 64
Study 23893464 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening intervention
Number of subjects: 32000
Study 21739497 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone
Number of subjects: 677
Study 21739497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 677
Study 20135885 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA)
Number of subjects: 0
Study 16728524 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness (more-fit individuals)
Number of subjects: 37
Study 16728524 — intervention group
Group type: COMPARATOR
Intervention: Soluble ICAM-1
Number of subjects: 37
Study 15144469 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch-pollen immunotherapy (IT)
Number of subjects: 25
Study 15144469 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic drugs only (Control)
Number of subjects: 25
Study 11776511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic tubal embryo transfer (h-TEST) using a catheter tapering at the distal 3 cm
Number of subjects: 60
Study 11776511 — intervention group
Group type: COMPARATOR
Intervention: Conventional embryo transfer (ET)
Number of subjects: 60
Study 11776511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic tubal embryo transfer (h-TEST) using a catheter tapering at the distal 5 cm
Number of subjects: 60
Study 9128316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg taken late in the evening, coupled with clarithromycin 250 mg b.i.d. and metronidazole 500 mg b.i.d. for the first 2 weeks.
Number of subjects: 80
Study 9128316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg taken before breakfast, coupled with clarithromycin 250 mg b.i.d. and metronidazole 500 mg b.i.d. for the first 2 weeks.
Number of subjects: 80
Study 8831524 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injected bilaterally into the external sphincter or puborectalis muscle (6 to 15 units)
Number of subjects: 4
Study 8831524 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 4
Study 2675434 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 46
Study 2675434 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 46
Study 1088951 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1.0 mg, intramuscular injection)
Number of subjects: 28
Study 1088951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1088951 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 28
Study 30843092 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) angioplasty
Number of subjects: 369
Study 30843092 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty without paclitaxel (control group)
Number of subjects: 369
Study 30843092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PCB and control)
Number of subjects: 369
Study 29916231 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy (performed when patients entered the active phase of labor, cervical dilatation 3‐5 cm, n=60)
Number of subjects: 120
Study 29916231 — intervention group
Group type: COMPARATOR
Intervention: Late amniotomy (membrane left intact, amniotomy reserved for specific indications, n=60)
Number of subjects: 120
Study 29916231 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 120
Study 29916231 — intervention group
Group type: COMPARATOR
Intervention: Late amniotomy
Number of subjects: 120
Study 26323726 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw trust with open mouth
Number of subjects: 121
Study 26323726 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw trust with teeth prottution
Number of subjects: 121
Study 26323726 — intervention group
Group type: EXPERIMENTAL
Intervention: Head tilt chin lift
Number of subjects: 121
Study 26323726 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple airway maneuvers
Number of subjects: 121
Study 23793449 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (n=16)
Number of subjects: 34
Study 23793449 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (n=18)
Number of subjects: 34
Study 23793449 — intervention group
Group type: COMPARATOR
Intervention: Comparison between isoflurane and propofol
Number of subjects: 34
Study 21464195 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine (Focetria) administered in 2 doses (dose 1 at enrollment and dose 2 after 4 weeks)
Number of subjects: 105
Study 21464195 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine (Focetria)
Number of subjects: 105
Study 19542766 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term intake of 'benifuuki' green tea (34 mg O-methylated catechin per day for 1.5 months before pollen exposure)
Number of subjects: 38
Study 19542766 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term intake of 'benifuuki' green tea
Number of subjects: 38
Study 19542766 — intervention group
Group type: COMPARATOR
Intervention: Short-term intake of 'benifuuki' green tea
Number of subjects: 38
Study 16731323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (10 mug bolus, n = 17)
Number of subjects: 30
Study 16731323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (20 mg bolus, n = 13)
Number of subjects: 30
Study 15217524 — intervention group
Group type: EXPERIMENTAL
Intervention: greens+
Number of subjects: 105
Study 15217524 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study 11751182 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg twice daily)
Number of subjects: 11
Study 11751182 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 11
Study 11751182 — intervention group
Group type: COMPARATOR
Intervention: Ozone exposure (0.27 ppm)
Number of subjects: 11
Study 9656405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin containing combined drug regimens
Number of subjects: 60
Study 9656405 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 60
Study 8480265 — intervention group
Group type: EXPERIMENTAL
Intervention: Resectoscope (group 1)
Number of subjects: 23
Study 8480265 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscissors (group 2)
Number of subjects: 23
Study 3168500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nonabsorbable antimicrobial agents (tobramycin, amphotericin B, polymyxin E) in addition to parenteral antibiotics
Number of subjects: 96
Study 3168500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nonabsorbable antimicrobial agents)
Number of subjects: 96
Study 3168500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nonabsorbable antimicrobial agents
Number of subjects: 96
Study 30307504 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h urine samples
Number of subjects: 3270
Study 30307504 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine estimates using individual concentrations and standard urine volume
Number of subjects: 3270